Page last updated: 2024-11-05

thalidomide and Peritoneal Carcinomatosis

thalidomide has been researched along with Peritoneal Carcinomatosis in 10 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)."6.79Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014)
"Celecoxib is a potent selective COX-2 inhibitor."5.32[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004)
"Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)."2.79Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014)
"Thalidomide was not more effective than tamoxifen in delaying recurrence or death but was more toxic."2.75Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation ( Benbrook, DM; Brady, MF; Darcy, KM; Edmonds, P; Hurteau, JA; Ivanov, I; Mannel, RS; McGuire, WP; Pearl, ML; Tewari, KS; Zanotti, K, 2010)
" The majority of adverse events were grades 1-2, including fatigue (25/80 cycles), nausea/vomiting (23/80), constipation (13/80), abdominal pain (17/80), rash (12/80), neutropenia (12/80), and anemia (12/80)."2.73Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. ( Chan, JK; Guo, HY; Husain, A; Teng, NN; Zhang, MM, 2007)
"Thalidomide is an anti-angiogenesis agent that has shown activity in some solid tumors."2.72Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. ( Chan, JK; Cheung, MK; Ciaravino, G; Husain, A; Manuel, MR; Teng, NN, 2006)
"Celecoxib is a potent selective COX-2 inhibitor."1.33[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. ( Hada, M; Horiuchi, T; Shinji, H, 2006)
"Celecoxib is a potent selective COX-2 inhibitor."1.32[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. ( Hada, M; Kazuhiro, M, 2004)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shen, P1
Thomas, CR1
Fenstermaker, J1
Aklilu, M1
McCoy, TP1
Levine, EA1
Gurung, S1
Fu, H1
Zhang, WW1
Gu, YH1
Hurteau, JA1
Brady, MF1
Darcy, KM1
McGuire, WP1
Edmonds, P1
Pearl, ML1
Ivanov, I1
Tewari, KS1
Mannel, RS1
Zanotti, K1
Benbrook, DM1
Hada, M2
Kazuhiro, M1
Horiuchi, T1
Shinji, H1
Biswas, G1
Narayanan, P1
Bhagwat, R1
Khadwal, A1
Bakshi, AV1
Parikh, PM1
Chan, JK2
Manuel, MR1
Ciaravino, G1
Cheung, MK1
Husain, A2
Teng, NN2
Zhang, MM1
Guo, HY1
Calligaris, L1
Marchetti, F1
Ventura, A1
Abramson, N1
Stokes, PK1
Luke, M1
Marks, AR1
Harris, JM1

Reviews

1 review available for thalidomide and Peritoneal Carcinomatosis

ArticleYear
Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Diagnosis, Differential;

2015

Trials

5 trials available for thalidomide and Peritoneal Carcinomatosis

ArticleYear
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms;

2014
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation
    Gynecologic oncology, 2010, Volume: 119, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormo

2010
Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Gynecologic oncology, 2006, Volume: 103, Issue:3

    Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; California; Drug Administration Schedule

2006
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
    Gynecologic oncology, 2007, Volume: 105, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence,

2007
Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-15, Volume: 20, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Sero

2002

Other Studies

4 other studies available for thalidomide and Peritoneal Carcinomatosis

ArticleYear
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Combined Modality Therapy; Dru

2004
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration

2006
Thalidomide in primary peritoneal mesothelioma.
    Journal of surgical oncology, 2006, Apr-01, Volume: 93, Issue:5

    Topics: Angiogenesis Inhibitors; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Thalidomide

2006
Intestinal plexiform neurofibromas.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2008, Volume: 40, Issue:7

    Topics: Angiogenesis Inhibitors; Child; Diagnosis, Differential; Female; Humans; Ileal Neoplasms; Mesentery;

2008